Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 9;14:1194123. doi: 10.3389/fimmu.2023.1194123

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Xu, Ding, Li, Peng, Ding, Huang, Zhou, Xie, Yan, Feng and Fan

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Pretreatment circulating chemokine CXCL12 levels predict outcomes of immunotherapy. (A) Response or nonresponse and (B) DCB or NDB of the patient proportions according to the levels of circulating CXCL12, stratified by the cutoffs of the top 33% (1/3) and bottom 67% (2/3). Pretreatment circulating CXCL12 levels in (C) patients who responded or did not respond to immunotherapy and in (D) patients with DCB or without DCB (NDB). Probability of (E) PFS or (F) OS according to circulating CXCL12 level, stratified by the cutoffs of the top 33% and bottom 67%. DCB, durable clinical benefit. NDB, no durable benefit.